Patents by Inventor Stephan R. Targan

Stephan R. Targan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220290235
    Abstract: This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.
    Type: Application
    Filed: January 28, 2022
    Publication date: September 15, 2022
    Inventors: Stephan R. Targan, Marla C. Dubinsky, Carol J. Landers, Ling Mei, Jerome I. Rotter, Kent D. Taylor
  • Patent number: 11440954
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: September 13, 2022
    Assignees: Prometheus Biosciences, Inc., Cedars-Sinai Medical Center
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • Patent number: 11434296
    Abstract: The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: September 6, 2022
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: David Q. Shih, Stephan R. Targan, Dalin Li, Janine Bilsborough
  • Publication number: 20220259320
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: February 28, 2022
    Publication date: August 18, 2022
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • Publication number: 20220251656
    Abstract: The present invention relates to methods of prognosing responsiveness to anti-TNF? therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNF? therapy in an individual diagnosed with IBD.
    Type: Application
    Filed: December 14, 2021
    Publication date: August 11, 2022
    Inventors: Jerome I. Rotter, Marla Dubinsky, Stephan R. Targan, Kent D. Taylor
  • Publication number: 20220162703
    Abstract: The present invention describes methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNASET2, TL1A and/or IFN-?. The invention further provides a process for patient identification and/or stratification.
    Type: Application
    Filed: October 28, 2021
    Publication date: May 26, 2022
    Inventors: Rebecca GONSKY, Stephan R. TARGAN, Richard L. DEEM, Philip FLESHNER, Dermot P. MCGOVERN, Janine BILSBOROUGH
  • Publication number: 20220153855
    Abstract: The aspects disclosed herein describe methods of identifying a subject that is non-responsive to anti-TNF therapy. The aspects disclosed herein further provide for a method of selecting a therapy for a subject with Inflammatory Bowel Disease (IBD), and treating the subject with the therapy.
    Type: Application
    Filed: October 22, 2021
    Publication date: May 19, 2022
    Inventors: Dermot McGOVERN, Stephan R. TARGAN, Dalin LI
  • Patent number: 11312768
    Abstract: The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TL17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: April 26, 2022
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Kathrin S. Michelsen, Stephan R. Targan
  • Patent number: 11292848
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: April 5, 2022
    Assignees: Prometheus Biosciences, Inc., Cedars-Sinai Medical Center
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • Patent number: 11268149
    Abstract: This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: March 8, 2022
    Assignee: Cedars-Sinai Medical Center
    Inventors: Stephan R. Targan, Marla C. Dubinsky, Carol J. Landers, Ling Mei, Jerome I. Rotter, Kent D. Taylor
  • Publication number: 20220056106
    Abstract: Described herein are methods, systems, compositions, and kits useful for the diagnosis and/or treatment of a disease or condition in a subject. The present disclosure relates to methods and systems for identifying and stratifying patients suitable for treatment with an IL18R1 modulator, as described herein.
    Type: Application
    Filed: August 6, 2021
    Publication date: February 24, 2022
    Inventors: Janine BILSBOROUGH, Stephan R. TARGAN, Dermot P. MCGOVERN
  • Patent number: 11236393
    Abstract: The present invention relates to methods of prognosing responsiveness to anti-TNF? therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNF? therapy in an individual diagnosed with IBD.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: February 1, 2022
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Jerome I. Rotter, Marla Dubinsky, Stephan R. Targan, Kent D. Taylor
  • Publication number: 20210395827
    Abstract: Described herein are methods, systems, compositions, and kits useful for the diagnosis and/or treatment of a disease or condition in a subject. The present disclosure relates to methods and systems for identifying and stratifying patients suitable for treatment with a SKAP2 modulator, as described herein.
    Type: Application
    Filed: August 6, 2021
    Publication date: December 23, 2021
    Inventors: Janine BILSBOROUGH, Stephan R. TARGAN, Dermot P. MCGOVERN
  • Publication number: 20210395824
    Abstract: Described herein are methods, systems, compositions, and kits useful for the diagnosis and/or treatment of a disease or condition in a subject. The present disclosure relates to methods and systems for identifying and stratifying patients suitable for treatment with a modulator of RNASET2, as described herein.
    Type: Application
    Filed: May 28, 2021
    Publication date: December 23, 2021
    Inventors: Rebecca Gonsky, Stephan R. Targan
  • Patent number: 11186872
    Abstract: Described herein are methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNA-SET2, TL1A and/or IFN-Y. The methods may comprise treating inflammatory bowel disease by administering a therapeutically effective amount of a therapeutic agent to a subject. Described further herein are processes for patient identification and/or stratification.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: November 30, 2021
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Rebecca Gonsky, Stephan R. Targan, Richard L. Deem, Philip Fleshner, Dermot P. McGovern, Janine Bilsborough
  • Publication number: 20210093718
    Abstract: Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohn's Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.
    Type: Application
    Filed: November 23, 2020
    Publication date: April 1, 2021
    Inventors: Janine Bilsborough, Stephan R. Targan, Bradley Henkle
  • Publication number: 20200216526
    Abstract: The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TL17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
    Type: Application
    Filed: April 18, 2019
    Publication date: July 9, 2020
    Inventors: Kathrin S. Michelsen, Stephan R. Targan
  • Publication number: 20200190203
    Abstract: The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 18, 2020
    Inventors: David Q. Shih, Stephan R. Targan, Dalin Li, Janine Bilsborough
  • Publication number: 20200157508
    Abstract: Induced pluripotent stem cell (iPSC)-based organoid technology has tremendous potential to elucidate the intestinal and colonic epithelium's role in health and disease. Described herein are methods and compositions for generation of intestinal and colonic cells from iPSCs. Derivation of iPSCs from subjected afflicted with early onset and very early onset Inflammatory Bowel Disease (IBD), serves as an excellent model for understanding disease pathogenesis.
    Type: Application
    Filed: May 18, 2018
    Publication date: May 21, 2020
    Applicant: Cedares-Sinai Medical Center
    Inventors: Robert Barrett, Clive Svendsen, Stephan R. Targan, Michael Workman, Dhruv Sareen
  • Publication number: 20200149110
    Abstract: This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.
    Type: Application
    Filed: November 13, 2019
    Publication date: May 14, 2020
    Inventors: Stephan R. Targan, Marla C. Dubinsky, Carol J. Landers, Ling Mei, Jerome I. Rotter, Kent D. Taylor